HLX43 DOSE 2
Sponsors
Shanghai Henlius Biotech
Conditions
Carcinoma of Head and/or NeckCarcinoma, HepatocellularGastric or Gastroesophageal Junction AdenocarcinomaNasopharyngeal Carcinoma (NPC)Non Small Cell Lung CancerSmall Cell Lung CancerSolid Tumor Cancer
Phase 1
Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
RecruitingNCT06742892
Start: 2025-03-03End: 2027-06-05Target: 90Updated: 2025-03-10
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
RecruitingNCT06839066
Start: 2025-04-02End: 2027-11-22Target: 70Updated: 2025-11-24
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RecruitingNCT06857279
Start: 2025-04-22End: 2029-01-30Target: 167Updated: 2026-03-05
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
RecruitingNCT07115485
Start: 2025-09-15End: 2028-09-30Target: 60Updated: 2025-11-18
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
RecruitingNCT07253142
Start: 2026-02-05End: 2028-06-19Target: 120Updated: 2026-07-21
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
RecruitingNCT07269782
Start: 2026-01-20End: 2026-11-30Target: 60Updated: 2026-06-04